Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 215 Rectal Neoplasms 85 Colonic Neoplasms 76 Stomach Neoplasms 56 Pancreatic Neoplasms 44 Neoplasm Metastasis 40 Esophageal Neoplasms 37 Neoplasms 28 Lung Neoplasms 27 Carcinoma, Non-Small-Cell Lung 20 Small Cell Lung Carcinoma 19 Adenocarcinoma Of Esophagus 19 Glioblastoma 18 Glioma 17 Neuroblastoma 16 Esophageal Squamous Cell Carcinoma 16 Brain Neoplasms 16 Breast Neoplasms 15 Sarcoma 11 Gliosarcoma 10 Biliary Tract Neoplasms 10 Central Nervous System Neoplasms 9 Astrocytoma 8 Adenocarcinoma 8 Oligodendroglioma 7 Medulloblastoma 7 Colorectal Cancer Metastatic 7 Rhabdomyosarcoma 6 Recurrence 6 Locally Advanced Rectal Cancer 6

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Irinotecan × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡